Securing comparator drugs in the EU is a complex process shaped by availability constraints, regulatory expectations, and competitive market behavior. But if we have the right planning, strong ...

In today’s ACT Brief, we examine the growing challenges of sourcing comparator drugs across the EU, highlight a new AI-driven ...

Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from ...

Using a single microcontroller port to drive a multi-digit LED display to help engineers with those last-minute design ...

The Financial Conduct Authority (FCA) has published updated proposals to its Value for Money (VFM) Framework consultation.

Ollin Biosciences has announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study ...

On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late ...

After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than ...

Epicrispr Reports Early Clinical Activity and Favorable Safety Profile in First-in-Human Epigenetic Editing Study for FSHD ...

Sadly, it means no such thing. This discussion overlooks an elementary distinction. There’s no neat or necessary connection between a “crash” — an abrupt reversal in financial markets, with effects ...

Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparatorIM1240's ...